QNRX · Quoin Pharmaceuticals Ltd. · Insider Trading

Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $161,461 of accrued interest outstanding ("Outstanding Debt") owed in connection with a note previously purchased by the Reporting Person was exchanged for 31,352 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $177,849 of accrued interest outstanding ("Outstanding Debt") owed in connection with a note previously purchased by the Reporting Person was exchanged for 34,534 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option grant was approved by the Compensation Committee of the Board of Directors of the Issuer on December 1, 2025.

The option vests in four annual installments with 20% vesting on each of December 1, 2026, 2027 and 2028 and 40% vesting on December 1, 2029.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

The Series K Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the Company's sale of a Priority Review Voucher (PRV).

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

The Series I Warrants will expire as follows: (i) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome, and (ii) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

The Series J Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

The Series H Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the Company's public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome.

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately, subject to a beneficial ownership cap.

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately, subject to a beneficial ownership cap.

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately, subject to a beneficial ownership cap.

Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately, subject to a beneficial ownership cap.

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately, subject to a beneficial ownership cap.

Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately, subject to a beneficial ownership cap.

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately, subject to a beneficial ownership cap.

Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

The Warrants were exercisable immediately, subject to a beneficial ownership cap.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028.

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028.